Viewing Study NCT06454968


Ignite Creation Date: 2025-12-24 @ 5:25 PM
Ignite Modification Date: 2026-01-01 @ 4:14 AM
Study NCT ID: NCT06454968
Status: RECRUITING
Last Update Posted: 2024-06-18
First Post: 2024-05-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Sponsor: Peking Union Medical College Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module